Dyax Soars As Rare-Disease Drug Wows Wall Street
Small biotech Dyax (DYAX) soared more than 52% to a 14-year high on the stock market Wednesday after it reported positive early-stage trial results for its rare-disease drug candidate late Tuesday. Dyax said its phase-one trial of DX-2930 showed positive safety and efficacy for 37 patients with hereditary angioedema (HAE), a rare, inheritable condition that leads to swelling of body parts, which is dangerous when it attacks such organs as the